LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy

Background: Familial hypercholesterolemia (FH), an autosomal dominant genetic disease with the elevated levels of low-density lipoprotein (LDL) cholesterol (LDL-C), increases the risk of coronary artery disease (CAD). The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is associated with...

Full description

Bibliographic Details
Main Authors:	Hamasaki, M. (Author), Hara, K. (Author), Kotani, K. (Author), Sakane, N. (Author)
Format:	Article
Language:	English
Published:	John Wiley and Sons Inc 2021
Subjects:	adult antilipemic agent APOB gene Article blood Cholesterol, LDL clinical effectiveness clinical feature colestilan drug effect drug efficacy drug response ezetimibe familial hypercholesterolemia female Female gain of function mutation gain-of-function mutation gene genetic hypercholesterolemia genetic variability genetics high throughput sequencing human Humans Hyperlipoproteinemia Type II Hypolipidemic Agents LDLR gene lipid-lowering therapy low density lipoprotein cholesterol low-density lipoprotein receptor major clinical study male Male middle aged Middle Aged mutation Mutation PCSK9 gene PCSK9 inhibitor PCSK9 protein, human proprotein convertase 9 Proprotein Convertase 9 risk factor statins treatment outcome
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy

Internet

Similar Items